|

Zalifrelimab Clinical Trials

2 actively recruiting trials across 2 locations

No change since May 2026

Also known as: AGEN1884, anti-CTLA4, checkpoint blockade

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • ImmunoGenesis1
  • Ann & Robert H Lurie Children's Hospital of Chicago1

Indications

  • Cancer2
  • Metastatic Head and Neck Squamous Cell Carcinoma1
  • Metastatic Pancreatic Cancer1
  • Diffuse Midline Glioma, H3 K27M-Mutant1
  • Metastatic Prostate Cancer1

Orange, California1 trial

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Children's Health Orange County (CHOC)

Phase 1

Houston, Texas1 trial

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

MD Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.